Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI
This article was originally published here
“The results of the Phase 1 clinical trial provide an early look at the safety, tolerability, durability, and potential biological activity of OTX-CSI,” said Michael Goldstein, MD, MBA,
The post Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!